Loading stock data…
SERA
$2.11+0.01 (+0.48%)
Market OpenUpdated 3:44 PM EDT
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sera Prognostics, Inc. in the Healthcare sector is trading at $2.11 with a market capitalization of $80M. Wall Street consensus targets $5.50 (2 analysts), implying a +160.7% move over the next 12 months. The stock is currently 48% below its 52-week high of $4.09, remaining 22.4% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +160.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$2.11
Potential Downside
0%
Whystock Fair Value$2.11
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$80.28M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.93
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-47.53%
Volume
Today's trading volume
49,555
Recent News
SunCar Technology Group And 2 Other Promising Penny Stocks For Savvy Investors
The market has shown positive momentum, climbing 1.3% over the last week and 28% in the past year, with earnings expected to grow by 17% per annum in the coming years. For investors willing to explore beyond well-known companies, penny stocks—often smaller or newer firms—can offer unique opportunities that align with current market growth trends. Despite being an older term, penny stocks remain relevant for those seeking potential value and growth, as they can provide financial strength and...
Sera Prognostics (SERA) Loses 27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Sera Prognostics (SERA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Will Sera Prognostics (NASDAQ:SERA) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Sera Prognostics, Inc. Q1 2026 Earnings Call Summary
Moby summary of Sera Prognostics, Inc.'s Q1 2026 earnings call
Sera Prognostics Q1 Earnings Call Highlights
Sera Prognostics (NASDAQ:SERA) reported first-quarter fiscal 2026 results and highlighted what management described as continued progress toward expanding awareness, access, and reimbursement pathways for its PreTRM test following publication of the full PRIME Study results in January. Commercial s